Clinical trial NCT06889025: Therapeutic Improvement in People with Schizophrenia Undergoing TACS/CBTp (transcranial Alternating Current Stimulation Applied Pre-cognitive Behavioral Therapy for Psychosis) Associated to Usual Medication Regimen
Official title: Electric and Physiological Markers, Underlying Mechanisms and Modulation of Cognitive Functioning and Therapeutic Improvement in Response to TACS/CBTp (transcranial Alternating Current Stimulation Applied At the Beginning of the Cognitive Behavioral Therapy for Psychosis Session) in Combination with the Usual Pharmacological Treatment in Schizophrenia
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Schizophrenia
Schizoaffective Disorder
Keywords: Schizophrenia
tACS
CBTp
Lead sponsor: Queen's University
Sponsor class: OTHER
Collaborators: name: Providence Care Hospital - Providence Care
name: Queen's University
First posted: 2025-03-21
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Mandatory Non-Experimental Procedures:

16 individual-basis (with duration of 50 minutes), weekly sessions (a form of talk therapy named cognitive behavioral therapy for psychosis) and a booster session of CBTp at each follow up (one month and three after intervention).

Mandatory Experimental Procedures The tASC with gamma band electric stimulation for 20 minutes at the beginning of the CBTp session is considered experimental and will only be done as part of this study.

The combination of tASC and CBTp intervention will be applied to the two different groups: one with gamma band electric stimulation for 20 minutes at the beginning of the CBTp session and another group with sham tACS/CBTp (the tACS is sham, but the CBTp is intervention).
Primary purpose: TREATMENT

Brief summary: The investigators are proposing a new, non-invasive therapeutic model using transcranial alternative current stimulation (tACS), to augment cognitive behavioral therapy for psychosis (CBTp) efficacy in individuals with schizophrenia (SZ). Using EEG brain oscillation activity, as a biomarker of the progression of cognitive deficits in SZ, the investigators aim to understand if addressing the oscillation perturbations could reduce the cognitive deficits. The investigators are using heart rate variability (HRV) as a biomarker of improvement of somatic and mental health. The investigators are aiming also for an analysis through a GBA+ lens, by using along with specific tests for psychosis (PANSS, NSA-16, etc.), the BEM Sex Role Inventory. Considering that cognitive and emotional status is gender dependent, the investigators expect that the therapeutic response could be gender specific. This is a prospective, randomized, repeated-measures, single-blind study design. Pre-intervention, eligible participants will be randomly assigned to one of two treatment arms. Arm 1 (tACS/CBTp n=14); Arm 2 (sham tACS/CBTp, n=14; tACS is sham, but CBTp is active). Intervention (16 weeks): participants in Arms 1 and 2 will receive once weekly tACS/ CBTp or sham tACS/CBTp. Post-intervention: follow-up visits at 4- and 12-weeks post-intervention (with a tACS/CBTp booster session provided each time). The chart review will search for: comorbid metabolic conditions, lab work abnormalities (glycemic level, Hb A, cholesterol), substances use, BMI, type of medication, side effects. Expected outcomes: Participants in Arm 1 will show a better improvement in psychosocial assessment scores, electrical brain activity (tendency to organize the neural oscillations in the gamma frequency range, mainly in frontal lobes) and heart activity (increased HRV). The timeline for recruitment, treatment and follow-up, is 18 months, followed by six months for data analysis, dissemination activities. Population: Individuals with SZ (DSM V criteria) stratified by age and sex. The investigators expect 150 potentially eligible patients from PCH-MHS, with 28 participants consenting to participate.

Detailed description: Rationale. 1% Canadians suffer from Schizophrenia (SZ), a neurodegenerative condition with a high rate of relapse, and important personal, familial and social burden, involving a high cost for care. The suicide rate for people with schizophrenia is over 20 times higher than the general population. While there is no cure, programs and treatments are available to help manage symptoms; however, these have limitations. 60% of patients with SZ do not respond adequately to treatment with medication alone (currently the primary, and often only approach). When CBT for Psychosis (CBTp) is used alongside medication, some improvements have been observed but the debilitating negative symptoms remain (such as reduction of emotional expression, lack of social involvement, inability to initiate goal-directed activities, etc.), which are key factors in long-term disability. A new treatment, transcranial alternating current stimulation (tACS) has therapeutic results in Alzheimer's.

The investigators propose combining these two therapies (CBTp and tACS), in a novel way to increase the overall improvement of negative symptoms in people living with schizophrenia.

Rationale: schizophrenia is characterized by abnormalities in neural circuitries resulting dysfunctional cognition and behavior. Recent randomized double blind clinical trials of tACS in Alzheimer's disease showed a significant improvement in memory performance, along with restoration of intracortical connectivity, as compared to sham tACS. The investigators propose similar cognitive enhancements in people living with schizophrenia. This technique has never been applied before in our studied population and has never used in combination with CBT.

Methodology. Description of intervention: CBTp: 16 individual-basis, 50 minutes length, weekly sessions (CBTp intervention) and 2 booster CBTp sessions at follow up visits (at one month and three months after intervention). tASC/CBTp: two different groups, one with gamma band electric stimulation for 20 minutes at the beginning of the CBTp session (after the first 20 minutes of brain stimulation the tACS device automatically stops and the device remains in place, while the CBTp session continues to run for 30 more minutes) and another group with sham tACS/CBTp (tACS is sham, but CBTp is intervention). For each group the investigators will follow the same protocol.

Number of visit (V): V. 1 (screening, week 0=W. 0); V.2 (enrollment/baseline, W.2, followed by starting intervention); V. 3 (Intervention Session 8/mid-term, W.9); V.4 (End of Intervention W. 17); V.5 (follow-up 1, W.21); V.6 (follow-up 2, W.29). Measures: Primary outcome measures/dependent variables: PANSS, Negative Symptom Assessment, Cognitive Flexibility Scale. Secondary physiological measures: EEG data and HRV: baseline, and end of intervention visit. Secondary psychological measures (WHO Disability Assessment Scale, Brief Betrayal Trauma Survey, BEM Sex Role Inventory Perceived Stress Scale, Working Alliance Inventory, Quality of Life and Enjoyment Scale, STROOP Color and Word test and Personal Evaluation in Transition of Treatment Scale). Eligibility screening measures: EEG; Columbia Suicide Severity Rating Scale; MOCA (over age 65): at screening. The chart review, performed at screening will help with selecting eligible participants. Statistical analysis plan: on SPSS, version 29, main tests will include repeated measures, mixed design analysis of variance and t-tests for two-group comparisons.

Analytical plan. This is a pilot study, and a sample size calculation is usually not necessary (however, there is a basic rule of 12 per group). Our primary focus is estimating average values and variability for planning larger subsequent studies. The investigators will consider all our clients (PCH_MHS) that meet diagnosis criteria (DSM V-TR) and are willing to be included to participate. Estimated sample size: N 150 (age/gender balancing target 75 female and 75 male); after screening the investigators estimate that the final number of participants will be 28, randomly assigned to one of the two intervention groups, following the same protocol (16 weekly tACS/CBTp intervention sessions, plus two booster sessions at the two follow-ups), but the intervention will be different, including sham tACS/CBTp and tACS/CBTp, respectively.

Objectives. Main objective: to elicit cognitive readiness, and therapeutic engagement as well as a better level of functioning and quality of life by adding tACS at the beginning of the CBTp session in participants living with schizophrenia, expecting at the endpoint an improvement in selected psychiatric and psychosocial assessment scores. A sham tACS condition, will ensure quality comparisons for the study group.

The investigators are using EEG brain oscillation activity as a biomarker of the progression of cognitive deficits in schizophrenia, and heart rate variability (HRV) as a biomarker of improvement of somatic and mental health. The investigators are aiming also for a sub-group analysis through a GBA+ lens, by using along with specific tests for psychosis (PANSS, NSA-16, etc.), the BEM Sex Role Inventory.

The investigators don't have healthy controls included in our study populations. Participants in one of the two intervention groups will not receive the current stimulation, but a placebo/sham tACS (the tACS is placebo but the CBTp is the intervention). Not receiving the low electric stimulation that may augment their response to psychotherapy (CBTp), their condition might not improve. The previous studies using only CBTp as intervention reported improvement of the illness (they will receive CBTp anyways). However, these study participants will continue their usual treatments, including antipsychotic treatment.

Devices. For measuring the Heart Rate Variability (HRV), the investigators will use an arm heart monitor. For the transcranial stimulation the investigators will use the tES device from NeuroMyst, featuring tDCS, tACS, tPCS, tRNS and tRCS waveforms as well as blind and double-blind placebo (sham) modes. Using advanced micro-electronics ensures accurate stimulation. Impedance changes can be detected and correct in 50 µ seconds. This means target current levels are super-accurate and super-stable, coming with an adjustable stimulus current of 0 up to 5 mA, with 25 µA increment and adjustable stimulation duration of 15 up to 40 min, with 5 s increment, as well as a study mode for sham stimulation. The electronic unit is intended to generate the electrical pulses of specified waveform, duration and repetition rate. The pulses are delivered to a study participant via stimulating electrodes positioned at participant's head according to the required technique. tES is an Investigational Device Exemption, with low risk for participants, that adhere to the international safety and recommended FDA guidelines.

Questionnaires. Study staff will ask each participant to answer questions in order to complete the study specific scales and assessments to check cognitive (mental) function, how well they are able to perform daily activities, their motivation and symptoms of schizophrenia status. Some of the questionnaires/assessments are self- assessments completed on paper; others will be completed by an interviewer (research staff). Trained study staff will give instructions on how to complete all of the questionnaires/ assessments. The participants will be allowed to take short breaks during these assessments if they need them. For some of the questionnaires/assessments, the participants should hold certain medications such as sleep or allergy medications (in particular benzodiazepines used to treat anxiety) at least 8 hours before the study visits. The study staff will tell them (before these visits) which medications should not be taken, if this applies to them. Some of the questionnaires/assessments must be done at approximately the same time of day. This is very important, and if the study participants are not able to arrive at the clinic on time for these visits, then the study staff may need to re-schedule the visit with them for another day. During the study visits the participants will be asked about their life experiences (positive and negative), relationships, and mental state (emotions, thoughts, feelings, symptoms); about their current experiences and problems they may be having, and information about their personal experience of schizophrenia, as this relates to the illness, stigma, its effects on their daily life such as stressors; about how they perceive their illness, about things that improve and worsen how they feel, and about their activities/events that they participate in or perceive around them. The names of the scales used in this study are: PANSS, Negative Symptom Assessment (NSA), Cognitive Flexibility Scale (CFS), WHO Disability Assessment Scale (WHODAS), Brief Betrayal Trauma Survey (BBTS), Perceived Stress Scale (PSS), Working Alliance Inventory (WAI), Quality of Life and Enjoyment Scale (QOL), STROOP Color and Word test, Columbia Suicide Severity Rating Scale (C-SSRS), BEM Sex Role Inventory and Personal Evaluation in Transition of Treatment Scale (PETIT), Montreal Cognition Assessment (MoCA) (over age 65).

The chart review at screening will help with selecting eligible participants. The chart review will search for: comorbid metabolic conditions, lab work abnormalities (glycemic level, Hb A, cholesterol), substances use, BMI, type of medication, side effects. Any chart reviews will be conducted by hospital-appointed individuals who have the privilege to access this information.

Sample size. This is a pilot study, and a sample size calculation is usually not necessary (however, there is basic rule of 12 per group). The investigators will consider all our clients (PCH-MHS) that meet diagnosis criteria (DSM V-TR) and are willing to participate. Our primary focus is estimating average values and variability for planning larger subsequent studies. Estimated sample size: N 150 (age/gender balancing target 75 female and 75 male); after screening the investigators estimate that the final number of participants will be 28, randomly assigned to one of the two intervention groups. The intervention groups will follow the same protocol (16 weekly intervention sessions with two follow-ups), but the intervention will be different, including sham tACS/CBTp and tACS/CBTp, respectively.

Recruitment. A letter and a poster will be distributed to psychiatrists at Providence Care Mental Health Services (PCH-MHS), informing them they can refer clients to the CBTp Clinic and they are invited to refer potential participants that meet an inclusion/exclusion criteria. Word of mouth and brochures/flyers will be prepared. The clinic staff or directly the participant will then contact our Research Coordinator/Assistant to communicate more information to the potential participant.

All participants included will have a diagnosed mental health disorder of schizophrenia or schizoaffective disorder. The investigators plan to include individuals who are both inpatients and outpatients at Providence Care Hospital. This includes participants who may be in long-term care. Potential participants in the study will be referred to the CBTp Clinic at Providence Care Hospital by the participant's primary treating psychiatrist. The treating psychiatrist will explain verbally and in writing that the referral is completely optional and that participation in any related study is entirely secondary and completely optional. During the first meeting at the CBTp Clinic, the potential participant will be informed about the study. The potential participant will be informed that their participation in the study is entirely optional alongside the standard clinic disclosures about privacy/confidentiality. They will have an opportunity to consider further involvement in a study by being given a break if they decide between meeting clinic personnel and being proposed written consent. Express written consent to participate in the study will be obtained by a member of the research team who is not in the circle of care of the participant (at arm's length). Participant withdrawal forms have been created to document any withdrawal accurately.

DISABILITY: Individuals will be excluded if they have severe or moderate intellectual disability or dual diagnosis, due to the nature of CBTp, that requires the learning of coping strategies, adequate attention and memory, engagement using speech, and appreciation of consequences of action, thoughts, behaviors, emotions, and beliefs which are limited in severe intellectual disability.

LANGUAGE AND LINGUISTIC PROFICIENCY: Individuals will be excluded if they do not have ability to understand English with reading level at or above grade 6. The ability for an individual to meaningfully engage in a CBTp talk therapy would be limited if their English level is limited to a grade 6 level and is thought to not be substantially beneficial to the individual.

AGE: Participants recruited will be included if they are aged 18-65. Individuals older than 65 years of age will be required to be assessed by the Montreal Cognitive Assessment and will be included in the study if results validate adequate cognitive performance. The Montreal Cognitive Assessment will be administered at the screening stage (score under 26 will be exclusion criteria).

Inclusion criteria. Individuals, with at least 5 years duration of illness, that meet diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual for Mental Disorders-5 and at least one residual positive symptom (as determined by the referring physician); no change in medication regimen for at least 1 months (minor dose adjustments and/or change in medication involving symptoms as sleep, anxiety or medical symptoms such as fever, pain, are permitted); persons of all genders between ages 18-65 (participants 65+ may be eligible depending on performance on cognitive assessment); ability to understand English with reading level at or above grade 6; able to understand and comply with the requirements of the study; provision of written informed consent.

Exclusion criteria: current illicit drug substance abuse; current suicidal ideation; current enrollment in CBTp or other formalized psychosocial interventions; undergone vagotomy or surgery upon the vagus nerve; comorbid neurological condition; severe or moderate intellectual disability; currently undergoing hormone therapy; under age 18; changes in medication/new hospitalization for worsening symptoms and/or presence of suicidal ideation. NOTE: for the last exclusions, these are no longer exclusion criteria for subjects that have passed visit 5, end of intervention, during follow-ups stage; however, the results of the follow-up visits will count at the final results, depending on the severity/imminent danger of symptoms and medication changes, at the best judgment of the principal investigator.

Patient care considerations. The main standard of care is medication management for adults with schizophrenia/schizoaffective disorder. When an individual requires other services or care, generally a referral is made to obtain these services. A proportion of adults with schizophrenia in the community may also have social or skill support via a community treatment team. The research Lab is situated in a hospital setting which is well resourced to support care in case of an emergency on site. Participants will be receiving their standard usual care throughout the study.

Premature withdrawal or suspension may occur if imminent safety concerns are disclosed to a study team member or a member of the CBTp Clinic by the participant. Withdrawal would be considered with the best interests and safety of the participant considered and foremost. An example of this would be if a participant indicated suicidal or homicidal ideation with a plan to carry out such an act at any point in time. After safety considerations are met and satisfied, the participant would be eligible to return or be included in the study.

The research team may temporarily or fully stop the study if there is any reason to believe that there is a medical reason why a participant may need to stop the study. Some of the reasons why this might happen are listed below: • their condition worsens or does not improve, and their doctor thinks they need a different treatment. • the study treatment or procedures are found to be unsafe or ineffective. • they are unable to follow instructions given to them about the study, or they otherwise cannot do or continue to do what they need to in order to participate in the study. • they develop another serious disease. • they become pregnant. • cancellation by the sponsor or regulatory authority, or for other unforeseen reasons that make it necessary to stop their study participation. If a participant is removed from the study from the study, the study doctor will explain to them why the participant was removed. A participant may also be temporarily suspended or stop their participation in the study in the event they require attention if it is believed there is a risk of harm to themselves or others. This may be indicated by a member in their circle of care or them or by the clinician-researchers on the team. In the event there is a risk of harm to themself or others, after the risk is no longer deemed significant, they may be able to continue the study.

Inform consent procedure. Potential participants will first verbally consent for their contact information to be shared with a Research Coordinator/Assistant to be contacted about the study, and to learn more about the study prior to agreeing to participate. A Research Coordinator/Assistant will contact the potential participant and arrange a meeting to discuss the study. At the meeting with the Research Coordinator/Assistant, the potential participant will learn about the study and will verbally be informed about content on the ICF form. The Letter with ICF will be presented and explained portion by portion, with the Research Coordinator/Assistant. The Research Coordinator/Assistant will allow the participant time, if they opt, on their own to review the form for 10 minutes, if they desire. They can even take home an unsigned document to ask for advice from their family, family physician, etc. If the participant agrees to proceed, they will be asked for their express written consent. Written consent will be re-assessed directly prior to undertaking the task. After this time, an appointment will be arranged for a screening visit. At each stage throughout the participants' engagement in the study, researchers will ask for verbal consent to continue. At this time, a participant will be told they have a choice to proceed or assess their willingness to participate. It is also foreseeable that if a participant comes to their respective appointments with the research team at subsequent points, willingness to participate will be implied. If a participant elects to withdraw from any aspect of the study, then, the research team has created a system to note participant withdrawal and how this was obtained for record-keeping reasons.

There are members of the research team who will be considered within the direct circle of care of the potential participant; where this is so, a member of the research team outside the direct circle of care of the potential participant will be designated as the individual to obtain written consent and also the individual who the participant can contact if the potential participant would like to withdraw/discontinue further participation. This arrangement will uphold the voluntary nature of consenting and minimize undue influence or power imbalance.

Where a participant has difficulty reading, a member of the research team will verbally communicate the information on a form/questionnaire if a participant requires clarification. Every effort will be made to try to help eligible participants with communication difficulties.

In this study the investigators don't enroll participants incapable to sign informed consent. To proactively monitor changes in the status of capacity, mid-way through the study, the research team will seek confirmation of the capacity status of the participant from healthcare personnel. As is typical ethical practice outside the scope of this study, if members of the CBTp Clinic (by way of observation/professional judgment) suspect a change in capacity in the participant, the participant's primary treating psychiatrist will be notified, and a re-assessment would take place.

Reimbursement. The investigators will give each participant $10 reimbursement to cover out-of-pocket expenses such as meals and parking for each of the 6 visits that are required as part of the study. Payments will be provided after each task is complete.

Some participants may incur expenses for food and travel (bus). Participants will be encouraged to bring a lunch or snack with them, as indicated on the ICF in light of this. The compensation will cover costs of bus transportation.

Potential risks. Transcranial alternative current stimulation: There are risks to taking part in any clinical study. If they receive a placebo/sham tACS, they will not receive the electric stimulation that may augment the response to psychotherapy (CBTp). If they receive active tACS before psychotherapy, then side effects may occur. Some of the side effects that may occur during this study can be treated. The adverse events are: very mild tingling sensation, fatigue and a light itching skin sensation under the stimulus, mild headache, dizziness, all these disappearing just after stimulation. With tACS no persistent adverse events have been reported, but the adverse events of the repetitive tACS application have not been fully clarified. In this type of stimulation technique, no serious adverse effects were reported.

Questionnaires: Some questionnaires may ask about stressful events in their life which may cause to them feel discomfort or remember things that may have upset them in their past. If they feel the content of a questionnaire is distressing, they are encouraged to let the study coordinator know at the time or at any later time. A member of research team can discuss this with them and refer this to a member of their care team whom they identify and consent to (the investigators will ask them for written consent to disclose this information if they decide). The participant's name will never be placed on a questionnaire to maintain their own privacy and to protect their confidentiality, and if they write their name by accident, a sticker that cannot be removed easily containing their participant ID will be placed over this to maintain their privacy. The participants may also feel frustrated or confused by language in the questionnaires. If there are words in any written material or things the investigators explain that require more clarify for them, members of the research team will be pleased to help them and clarify details to their satisfaction.

Data security and scientific advancements: Even with data security protections in place, there is a risk that participant information could be released by accident.

The plan to mitigate the risk of psychological or emotional risk will be managed by the research team, and training interviewers to administer questionnaires to be thoughtful, sensitive, and cognizant of the types of questions they are asking and anticipating these effects and potential thought processes the participants may experience. These are essential strategies to ensure sensitive and polite communication and help researchers learn how to read verbal and non-verbal communication that may communicate discomfort. In case of a confidentiality breach, in spite of the safeguards in place, the investigators will immediately take steps to contain it, notify the participant, investigate and remediate.

The chart review will search for risk factors that may influence the participant response to study intervention: comorbid metabolic conditions, lab work abnormalities (glycemic level, Hb A, cholesterol), substances use, BMI, type of medication, side effects. Only personnel with designated hospital appointments (Departmental Assistant Status/Departmental Research Assistant Status at Providence Care Hospital) or physicians at Providence Care Hospital who are part of the research team will have access to any Personal Health Information. The access will be necessary to corroborate information given during Interviewer-Administered Interviews linked with questionnaires.

Access to medical records and/or study data will be limited to authorized personnel. Electronic data will be stored on a hospital or other institutional network with firewalls and other security and back-up measures in place. Data stored on laptops or mobile devices will be encrypted. Paper copies of study data will be stored in locked filing cabinets in a secure location.

Dr. Felicia Iftene, A. Farcas will have access to data. Data will be stored 15 years under participant ID numbers (anonymized) on the electronic data will be stored on a hospital or other institutional network with firewalls and other security and back-up measures in place.

Any data that exists in identifiable form (Name) will immediately, at first opportunity, be converted and replaced with participant ID. A Master-List of code-linking identifiers will only be held by Dr. Iftene, A. Farcas for 15 years after the end of study.

Data collected on paper, with the exception of the consent form, will be anonymized. Data collected on paper will be stored in the archive, in locked filing cabinets at Providence Care Hospital. The data will be kept for 15 years in a de-identified format, in the archive.

Impact Novelty and innovation. Our goal is to find solutions to improving treatment trajectories for individuals suffering from schizophrenia. With this study, the investigators will be the first to examine the possibility of augmenting the efficacy of CBTp by inducing neural oscillations within the gamma range add-on to the CBTp session, contributing new knowledge to literature.

Clinical benefit. 28 clients will have the opportunity to benefit from our CBTp intervention with or without tACS.

Social costs. The new type of intervention will allow for personalized and highly impactful treatment. This will lead to quality-of-life improvement for participants as well as for support members (family and caregivers) and will reduce health care costs.

Dissemination. The investigators anticipate publishing up to 5 new peer reviewed publications and present the results to different scientific events. This pilot study will generate a data set that will support future grant application.

Education. Two master students from the Center for Neuroscience Studies, are working on this project, under the supervision of Dr. Iftene and Dr. O'Brien.

Eligibility criteria: Inclusion Criteria:

1. Individuals, with at least 5 years duration of illness, that meet diagnostic criteria for schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual for Mental Disorders-5 and at least one residual positive symptom (as determined by the referring physician);
2. no change in medication regimen for at least 1 months (minor dose adjustments and/or change in medication involving symptoms as sleep, anxiety or medical symptoms such as fever, pain, are permitted);
3. all genders between ages 18-65 (participants 65+ may be eligible depending on performance on cognitive assessment);
4. ability to understand English with reading level at or above grade 6;
5. able to understand and comply with the requirements of the study;
6. provision of written informed consent.

Exclusion Criteria:

1. current illicit drug substance abuse;
2. current suicidal ideation;
3. current enrollment in CBTp or other formalized psychosocial interventions;
4. undergone vagotomy or surgery upon the vagus nerve;
5. comorbid neurological condition;
6. severe or moderate intellectual disability;
7. currently undergoing hormone therapy;
8. under age 18.

NOTE: changes in medication/new hospitalization for worsening symptoms and/or presence of suicidal ideation are no more exclusion criteria for subjects that have passed visit 5 (end of intervention, during follow-ups stage); however the results of the follow-up visits will count at the final results, depending on the severity/imminent danger of symptoms and medication changes, at the best judgment of the principal investigator

Primary outcomes:
measure: PANSS (Positive and Negative Symptoms of Schizophrenia Scale)
timeFrame: Positive and Negative Symptoms of Schizophrenia scale will be applied at: Visit 1, Screening (Week 0); Visit 4, End of intervention (Week 17); Visit 5,Follow-up 1 (Week 21); Visit 6 Follow-up 2 (Week 29).
measure: NSA-16 (Negative Symptom Assessment)
timeFrame: Negative Symptom Assessment-16: Visit 2, Baseline (Week 1); Visit 4, End of intervention (Week 17); Visit 5, Follow-up 1 (Week 21); Visit 6 Follow-up 2 (Week 29).
measure: CFS (Cognitive Flexibility Scale)
timeFrame: Cognitive Flexibility Scale: Visit 2, Baseline (Week1 ); Visit 3 Mid point of intervention (Week 9); Visit 4, End of intervention (Week 17); Visit 5, Follow-up 1 (Week 21); Visit 6, Follow-up 2 (Week 29).
Secondary outcomes:
measure: Heart Rate Variability (HRV)
timeFrame: The Heart Rate Variability will be determined at Visit 2, Week 1, before and immediately after the first intervention (tACS/CBTp); it will be determined also pre and post the 16th intervention, Visit 4, Week 17.
measure: Electroencephalogram (EEG)
timeFrame: Electroencephalogram will be performed at the Visit 1, Screening (Week 0) and Visit 5 End of intervention (Week 17) - before and at the end of intervention (the 16 tAC/CBTp sessions)
measure: World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0)
timeFrame: The WHODAS 2.0 will be performed at: Visit 2, Baseline (Week 1), Visit 4, End of intervention (Week 17), Visit 5, Follow-up 1 (Week 21), Visit 6, Follow-up 2 (Week 29).
measure: The Quality-of-Life Enjoyment and Satisfaction Questionnaire Short Form (Q-Les-Q-SF)
timeFrame: The Q-Les-Q-SF will be performed at: Visit 2, Baseline (Week 1); Visit 3 Mid-way intervention (Week 9), Visit 4 End of intervention (Week 17); Visit 5 Follow-up 1 (Week 21); Visit 6 Follow-up 2 (Week 2.9)
measure: Brief Betrayal Trauma Survey (BBTS)
timeFrame: Brief Betrayal Trauma Survey will be performed at Visit 2, Baseline.
measure: Perceived Stress Scale (PCP)
timeFrame: Perceived Stress Scale (PCP) will be performed at: Visit 2, Baseline (Week 1), Visit 4, End of intervention (Week 17), Visit 5, Follow-up 1 (Week 21), Visit 6, Follow-up 2 (Week 29).
measure: The Personal Evaluation of Transitions in Treatment (PETiT).
timeFrame: The Personal Evaluation of Transitions in Treatment (PETiT) will be performed at: Visit 2, Baseline (Week 1), Visit 4, End of intervention (Week 17), Visit 5, Follow-up 1 (Week 21), Visit 6, Follow-up 2 (Week 29).
measure: The Working Alliance Inventory - Short Revised (WAI-SR) - both forms: for client and therapist.
timeFrame: The Working Alliance will be tested at Visit 3, Mid-term through intervention (Week 9) and Visit 4, End of intervention (Week 17).
measure: The BEM Sex Role Inventory (BSRI)
timeFrame: The BEM Sex Role Inventory (BSRI) is performed at Visit 1, Screening (Week 0)
measure: The STROOP Color and Word Test
timeFrame: The STROOP Color and Word Test will be applied at Visit 2, Baseline (Week 0) and at Visit 4, End of intervention (Week 17).
Other outcomes:
measure: Eligibility Screening Measures: Columbia Suicide Severity Rating Scale
timeFrame: At Screening, Visit 1(Week 0).
measure: Eligibility Screening Measures: The Montreal Cognition Assessment (MoCA), for participants over age of 65.
timeFrame: The Montreal Cognition Assessment MoCA will be performed at Visit 1, Screening (Week 0), to participants over age of 65 (to exclude a possible cognitive decline).
Locations:
city: Kingston
country: Canada
facility: Providence Care Hospital
state: Ontario
Study officials:
affiliation: Department of Psychiatry, Queen's University
name: Felicia Iftene, Associate Professor, Md, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Tsuchimoto R, Kanba S, Hirano S, Oribe N, Ueno T, Hirano Y, Nakamura I, Oda Y, Miura T, Onitsuka T. Reduced high and low frequency gamma synchronization in patients with chronic schizophrenia. Schizophr Res. 2011 Dec;133(1-3):99-105. doi: 10.1016/j.schres.2011.07.020. Epub 2011 Aug 16.
citation: Benussi A, Cantoni V, Cotelli MS, Cotelli M, Brattini C, Datta A, Thomas C, Santarnecchi E, Pascual-Leone A, Borroni B. Exposure to gamma tACS in Alzheimer's disease: A randomized, double-blind, sham-controlled, crossover, pilot study. Brain Stimul. 2021 May-Jun;14(3):531-540. doi: 10.1016/j.brs.2021.03.007. Epub 2021 Mar 21.
citation: Turner DT, Burger S, Smit F, Valmaggia LR, van der Gaag M. What Constitutes Sufficient Evidence for Case Formulation-Driven CBT for Psychosis? Cumulative Meta-analysis of the Effect on Hallucinations and Delusions. Schizophr Bull. 2020 Sep 21;46(5):1072-1085. doi: 10.1093/schbul/sbaa045.
citation: Jones M, McDermott B, Oliveira BL, O'Brien A, Coogan D, Lang M, Moriarty N, Dowd E, Quinlan L, Mc Ginley B, Dunne E, Newell D, Porter E, Elahi MA, O' Halloran M, Shahzad A. Gamma Band Light Stimulation in Human Case Studies: Groundwork for Potential Alzheimer's Disease Treatment. J Alzheimers Dis. 2019;70(1):171-185. doi: 10.3233/JAD-190299.
citation: Best MW, Milanovic M, Iftene F, Bowie CR. A Randomized Controlled Trial of Executive Functioning Training Compared With Perceptual Training for Schizophrenia Spectrum Disorders: Effects on Neurophysiology, Neurocognition, and Functioning. Am J Psychiatry. 2019 Apr 1;176(4):297-306. doi: 10.1176/appi.ajp.2018.18070849. Epub 2019 Mar 8.
citation: Farcas A, Iftene F. Findings, limitations and new directions in tACS studies in schizophrenia research: A scoping review. J Psychiatr Res. 2022 Jul;151:291-298. doi: 10.1016/j.jpsychires.2022.04.036. Epub 2022 Apr 29.